Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

As J&J Sees Continued Drug Price Declines, CEO Urges Slow Policy Change Via Trump's Blueprint

Executive Summary

J&J told investors to anticipate negative net drug pricing of 4%-6% across its portfolio in 2018, following a 4.6% negative impact in 2017. CEO Alex Gorsky also cautioned against changing drug pricing policy too quickly.

Advertisement

Related Content

J&J Pharma Growth Led By Oncology; Firm Tries To Assuage Zytiga Concerns
Pharma Q3 Results Preview: J&J, Novartis & Roche
J&J's Invokana Slows CKD Progression In Diabetes
Pfizer Agrees To Roll Back Prices On 40 Drugs, Yielding To Pressure From Trump
Trump Tries To Shame A Defiant Pfizer On Drug Pricing
Trump Drug Pricing Plan Includes Part D Surprises, Challenges PBM Business Model
J&J Stays Within Price Pledge, But Average Doesn't Tell The Whole Story, Analyst Says
Janssen Emphasizes Average Net Price Decline As Transparency Momentum Builds In States
FDA's Gottlieb: 'Pricing And Reimbursement Mischief' Holding Back Biosimilar Market
Pfizer Sets The Stage For A Biosimilar Showdown Over Exclusive Contracts

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123429

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel